Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

Sabrina Lyngbye Wendt; Ajenthen Ranjan; Jan Kloppenborg Møller; Signe Schmidt; Carsten Boye Knudsen; Jens Juul Holst; Sten Madsbad; Henrik Madsen; Kirsten Nørgaard; John Bagterp Jørgensen

Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

Sabrina Lyngbye Wendt
, Ajenthen Ranjan
, Jan Kloppenborg Møller
, Signe Schmidt
, Carsten Boye Knudsen
, Jens Juul Holst
, Sten Madsbad
, Henrik Madsen
, Kirsten Nørgaard
, John Bagterp Jørgensen

Research output: Contribution to conference › Poster › Research

491 Downloads (Orbit)

Abstract

Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determine
the glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.

Original language	English
Publication date	2017
Number of pages	1
Publication status	Published - 2017
Event	Advanced Technology and Treatments for Diabetes 2017 - Paris, France Duration: 15 Feb 2017 → 18 Feb 2017

Conference

Conference	Advanced Technology and Treatments for Diabetes 2017
Country/Territory	France
City	Paris
Period	15/02/2017 → 18/02/2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

ATTD2017 SLW finalFinal published version, 442 KB

OpenUrl availability

Full text

Cite this

Wendt, S. L., Ranjan, A., Møller, J. K., Schmidt, S., Boye Knudsen, C., Holst, J. J., Madsbad, S., Madsen, H., Nørgaard, K., & Jørgensen, J. B. (2017). Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes. Poster session presented at Advanced Technology and Treatments for Diabetes 2017, Paris, France.

@conference{32a8110aaeac4ba5974e47325de683bf,

title = "Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes",

abstract = "Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determine the glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.",

author = "Wendt, \{Sabrina Lyngbye\} and Ajenthen Ranjan and M{\o}ller, \{Jan Kloppenborg\} and Signe Schmidt and \{Boye Knudsen\}, Carsten and Holst, \{Jens Juul\} and Sten Madsbad and Henrik Madsen and Kirsten N{\o}rgaard and J{\o}rgensen, \{John Bagterp\}",

year = "2017",

language = "English",

note = "Advanced Technology and Treatments for Diabetes 2017, ATTD 2017 ; Conference date: 15-02-2017 Through 18-02-2017",

}

TY - CONF

T1 - Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

AU - Wendt, Sabrina Lyngbye

AU - Ranjan, Ajenthen

AU - Møller, Jan Kloppenborg

AU - Schmidt, Signe

AU - Boye Knudsen, Carsten

AU - Holst, Jens Juul

AU - Madsbad, Sten

AU - Madsen, Henrik

AU - Nørgaard, Kirsten

AU - Jørgensen, John Bagterp

PY - 2017

Y1 - 2017

N2 - Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determine the glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.

AB - Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determine the glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.

M3 - Poster

T2 - Advanced Technology and Treatments for Diabetes 2017

Y2 - 15 February 2017 through 18 February 2017

ER -

Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

Abstract

Conference

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this